

State of Oklahoma SoonerCare Rozlytrek[®] (Entrectinib) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
	Drug Information	
Pharmacy billing (NDC:) Start Date (or date of next dose):	
Dose:	Regimen:	
	Billing Provider Informa	ation
Provider NPI:	Provider Name:	
Provider Phone:	Provider Fax:	
	Prescriber Information	on
Prescriber NPI:	Prescriber Name:	
		Specialty:
	Criteria	
 Solid Tumors A. Does diagnosis inc. YesNo B. Is disease metastation C. Is member a surgican D. Has disease program E. Is a satisfactory alternation If answer is none of the second sec	tic? Yes No sitive? Yes No lude <i>NTRK</i> gene fusion without a known	5 5 :
3. Has the member experience If yes, please specify adverse	dence of progressive disease while on e	to entrectinib therapy? Yes No
Prescriber Signature:	D	Date: rmation is true and correct to the best of
I certify that the indicated treati knowledge.	ment is medically necessary and all info	rmation is true and correct to the best of

Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:	CONFIDENTIALITY NOTICE
University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4	This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.
·	